CN115368438A - 吡咯烷酰胺衍生物及其制备和使用方法 - Google Patents

吡咯烷酰胺衍生物及其制备和使用方法 Download PDF

Info

Publication number
CN115368438A
CN115368438A CN202210589872.0A CN202210589872A CN115368438A CN 115368438 A CN115368438 A CN 115368438A CN 202210589872 A CN202210589872 A CN 202210589872A CN 115368438 A CN115368438 A CN 115368438A
Authority
CN
China
Prior art keywords
compound
disease
composition
inflammatory
optical isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210589872.0A
Other languages
English (en)
Chinese (zh)
Inventor
崔吉惇
李相达
阿里·伊姆兰
蔡钟学
朴锡熙
全文国
李延洙
李光浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University School Industry Cooperation
Korea Research Institute of Chemical Technology KRICT
Original Assignee
Sungkyunkwan University School Industry Cooperation
Korea Research Institute of Chemical Technology KRICT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sungkyunkwan University School Industry Cooperation, Korea Research Institute of Chemical Technology KRICT filed Critical Sungkyunkwan University School Industry Cooperation
Priority to CN202210589872.0A priority Critical patent/CN115368438A/zh
Publication of CN115368438A publication Critical patent/CN115368438A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202210589872.0A 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法 Pending CN115368438A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210589872.0A CN115368438A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20150097040 2015-07-08
CN201680020220.8A CN107531753A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法
PCT/US2016/041563 WO2017008033A1 (en) 2015-07-08 2016-07-08 Pyrrolidine carboxamido derivatives and methods for preparing and using the same
CN202210589872.0A CN115368438A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680020220.8A Division CN107531753A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法

Publications (1)

Publication Number Publication Date
CN115368438A true CN115368438A (zh) 2022-11-22

Family

ID=57686085

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210589872.0A Pending CN115368438A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法
CN201680020220.8A Pending CN107531753A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680020220.8A Pending CN107531753A (zh) 2015-07-08 2016-07-08 吡咯烷酰胺衍生物及其制备和使用方法

Country Status (24)

Country Link
US (4) US20170008924A1 (https=)
EP (1) EP3265443B1 (https=)
JP (1) JP6692371B2 (https=)
KR (1) KR101963559B1 (https=)
CN (2) CN115368438A (https=)
AU (1) AU2016290963B2 (https=)
BR (1) BR112017022857B1 (https=)
CA (1) CA2980001C (https=)
CL (1) CL2017002689A1 (https=)
CO (1) CO2017010530A2 (https=)
DK (1) DK3265443T3 (https=)
EA (1) EA033342B1 (https=)
ES (1) ES2784703T3 (https=)
IL (1) IL254327B (https=)
MX (1) MX2017013335A (https=)
MY (1) MY189670A (https=)
NZ (1) NZ735250A (https=)
PH (1) PH12017501790A1 (https=)
PL (1) PL3265443T3 (https=)
PT (1) PT3265443T (https=)
SA (1) SA517390034B1 (https=)
SG (1) SG11201707145QA (https=)
UA (1) UA121890C2 (https=)
WO (1) WO2017008033A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ735250A (en) 2015-07-08 2020-08-28 Research & Business Found Sungkyunkwan Univ Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EP3759070A4 (en) * 2018-02-28 2021-12-08 Bridge Biotherapeutics, Inc. WATER-SOLUBLE SALTS OF LIPID PEPTIDES AND THEIR PREPARATION AND USE PROCESSES
SG11202104802RA (en) 2018-11-08 2021-06-29 Arizona Board Of Regents On Behalf Arizona State Univ Synthetic immunomodulation with a crispr super-repressor in vivo
KR102104507B1 (ko) 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN114585383B (zh) * 2019-10-17 2024-04-19 艾弼生物科技有限公司 包含rip激酶抑制剂的用于防脱发或促生发的组合物
KR102268702B1 (ko) * 2019-10-17 2021-06-24 주식회사 에피바이오텍 Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물
KR102394875B1 (ko) * 2021-05-11 2022-05-06 주식회사 비드테크 피롤리딘을 링커로 포함하는 화합물 및 이를 포함하는 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20130237484A1 (en) * 2010-09-09 2013-09-12 Nanao Intelligent Biomedical Engineering Corporation Co., Ltd. Human-derived cell-permeable peptide bioactive peptide conjugate, and use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3839127A1 (de) * 1988-11-19 1990-05-23 Hoechst Ag Pyrrolidon-2-carbonsaeure-derivate mit psychotroper wirkung
AUPM906594A0 (en) 1994-10-26 1994-11-17 Peptide Technology Limited Synthetic polyunsaturated fatty acid analogues
ES2243996T3 (es) * 1996-05-01 2005-12-01 Ortho-Mcneil Pharmaceutical, Inc. Derivados carboxamida de pirrolidina, piperidina y hexahidroazepina utilizados en el tratamiento de trastornos de trombosis.
EP1004578B1 (en) * 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
JP2002297664A (ja) 2001-04-03 2002-10-11 Fuji Photo Film Co Ltd 画像データ提供装置および画像データ提供プログラム
WO2003007876A2 (en) 2001-06-25 2003-01-30 University Of Massachusetts N-fatty acid-amino acid conjugates and therapeutic uses
DE10259672A1 (de) * 2002-12-18 2004-07-01 Basf Ag Verfahren zur Herstellung von Alkoxycarbonylamino-triazinen
JP2006157623A (ja) * 2004-11-30 2006-06-15 Funai Electric Co Ltd 放送受信装置
WO2006113942A2 (en) * 2005-04-20 2006-10-26 Schering Corporation Method of inhibiting cathepsin activity
US7842662B2 (en) * 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
CN102067197A (zh) 2008-06-26 2011-05-18 夏普株式会社 显示装置和电子设备
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
KR101033041B1 (ko) 2008-11-13 2011-05-09 조선대학교산학협력단 경보장치 고정 장치
WO2010059922A1 (en) * 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
KR101151878B1 (ko) 2010-06-08 2012-05-31 미원상사주식회사 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물
KR20100110282A (ko) 2010-08-16 2010-10-12 황규태 쓰레기봉투용 뚜껑
KR20120048864A (ko) 2010-11-08 2012-05-16 주식회사 네오디엠 트리 펩타이드 유도체를 함유한 아토피 피부염 예방 및 치료용 조성물과 그 제조방법
KR20130038426A (ko) 2011-10-07 2013-04-18 성균관대학교산학협력단 지방산이 결합된 항당뇨 펩티드가 소수성 결합된 글리콜 키토산 히드로겔 및 이를 포함하는 당뇨병 예방 또는 치료용 약학적 조성물
KR101359886B1 (ko) 2011-12-28 2014-02-12 성균관대학교산학협력단 스매드 6번(Ｓｍａｄ６)으로부터 유래된 펩타이드를 유효성분으로 포함하는 패혈증 또는 패혈성 쇼크의 치료용 조성물
US20150368197A1 (en) * 2012-06-21 2015-12-24 Radikal Therapeutics Ins. Compositions and methods for treatment of inflammatory diseases of the lung
WO2015057820A2 (en) * 2013-10-15 2015-04-23 Roberts S Kenny Peptide constructs and well-defined aggregates thereof
NZ735250A (en) 2015-07-08 2020-08-28 Research & Business Found Sungkyunkwan Univ Pyrrolidine carboxamido derivatives and methods for preparing and using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103298935A (zh) * 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20130237484A1 (en) * 2010-09-09 2013-09-12 Nanao Intelligent Biomedical Engineering Corporation Co., Ltd. Human-derived cell-permeable peptide bioactive peptide conjugate, and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOANNIE M. ALLAIRE 等: "Loss of Smad5 leads to the disassembly of the apical junctional complex and increased susceptibility to experimental colitis", 《AM J PHYSIOL GASTROINTEST LIVER PHYSIOL》, 6 January 2011 (2011-01-06) *
KABANOV等: "Lipid modification of proteins and their membrane transport", 《PROTEIN ENGINEERING》, 11 October 1989 (1989-10-11), pages 39 - 40 *

Also Published As

Publication number Publication date
SG11201707145QA (en) 2017-10-30
WO2017008033A1 (en) 2017-01-12
CL2017002689A1 (es) 2018-04-20
CA2980001C (en) 2021-05-04
MY189670A (en) 2022-02-24
PT3265443T (pt) 2020-02-14
CO2017010530A2 (es) 2018-01-05
IL254327A0 (en) 2017-11-30
ES2784703T3 (es) 2020-09-30
US20180208625A1 (en) 2018-07-26
PL3265443T3 (pl) 2020-06-29
WO2017008033A8 (en) 2017-11-16
SA517390034B1 (ar) 2021-12-23
EP3265443B1 (en) 2020-01-08
US20170008924A1 (en) 2017-01-12
JP2018519244A (ja) 2018-07-19
IL254327B (en) 2021-04-29
CN107531753A (zh) 2018-01-02
HK1243078A1 (en) 2018-07-06
CA2980001A1 (en) 2017-01-12
BR112017022857A2 (pt) 2018-07-17
EP3265443A4 (en) 2018-11-07
US20230018246A1 (en) 2023-01-19
KR20170127000A (ko) 2017-11-20
KR101963559B1 (ko) 2019-03-28
DK3265443T3 (da) 2020-03-09
PH12017501790A1 (en) 2018-04-02
EA201791945A1 (ru) 2018-06-29
AU2016290963A1 (en) 2017-09-28
NZ735250A (en) 2020-08-28
AU2016290963B2 (en) 2019-06-27
JP6692371B2 (ja) 2020-05-13
EP3265443A1 (en) 2018-01-10
EA033342B1 (ru) 2019-09-30
MX2017013335A (es) 2018-06-06
US20240352067A1 (en) 2024-10-24
BR112017022857B1 (pt) 2023-09-26
UA121890C2 (uk) 2020-08-10
US11365215B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
US20240352067A1 (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
TW200942239A (en) Phenylacetamide derivatives
US12054477B2 (en) Prodrug of pyrrolidone derivatives as glucokinase activator
US20250152596A1 (en) Method of treating pain or interstitial cystitis using indole compound
DK3000466T3 (en) INHIBITOR FOR RETINOCHOROIDAL DISEASES
JP2022106788A (ja) 脂質化ペプチドの水溶性塩、その製造方法および用途
JPWO2017217071A1 (ja) セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤
HK1243078B (en) Pyrrolidine carboxamido derivatives and methods for preparing and using the same
EP4192461A1 (en) Method for treatment of cytokine release syndrome
US20230128304A1 (en) Benzimidazole compound for the treatment of metabolic disorders
HK40049577B (en) Indole compound for treating interstitial cystitis
HK40049577A (en) Indole compound for treating interstitial cystitis
KR20220126122A (ko) 섬유증의 치료 또는 완화용 약학 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination